Long-term Follow-up and Correlative Analysis of Two Phase II Trials of Rituximab and Lenalidomide Followed by Continuous Lenalidomide in Untreated and Relapsed/Refractory Indolent Lymphoma.
Joseph M TuscanoChristina PohPaul KaesbergGuilluame LuxardiAlexander A MerleevAlina MarusinaAnn BrunsonAaron RosenbergBrian A JonasEmanual MaverakisPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Rituximab plus lenalidomide followed by continuous lenalidomide is effective with manageable toxicity in patients with previously untreated and R/R iNHL. This regimen produces durable remissions, even in heavily pretreated patients, with some lasting greater than 10 years. GranB+ CD8+ T cells, B cells, and plasma IFNγ allowed prediction of LTCR but need validation in larger trials.